Trial Profile

Imaging of Solid Tumors Using FAP-2286

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gallium-68 FAP 2286 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Colon cancer; Head and neck cancer; Male breast cancer; Pancreatic cancer; Prostate cancer; Sarcoma; Solid tumours
Focus Adverse reactions; Diagnostic use; First in man

Most Recent Events

31 Dec 2025 Protocol has been amended(Time frame of primary endpoint and planned patient number).
31 Dec 2025 Planned number of patients changed from 131 to 191.
21 Nov 2024 Planned number of patients changed from 116 to 131.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com